Nod for schizophrenia drug with no jitters
The US drugs regulator approves Caplyta, which in trials did not cause uncomfortable akathisia sensations
The US Food and Drug Administration (FDA) has approved Intra-Cellular Therapies’s investigational drug to treat schizophrenia, the company said on Monday, sending its shares soaring 40%.
The treatment, Caplyta, is the drug developer’s lead candidate that has shown to regulate three neurotransmitter systems — serotonin, dopamine and glutamate — linked to severe mental illnesses. The approval comes with a boxed warning, the FDA’s harshest, saying the drug is not for the treatment of patients with dementia-related psychosis...